Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ. Becher OJ, et al. Among authors: kolesar jm. PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017. PLoS One. 2017. PMID: 28582410 Free PMC article. Clinical Trial.
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. Schelman WR, et al. Among authors: kolesar jm. Cancer Chemother Pharmacol. 2009 May;63(6):1147-56. doi: 10.1007/s00280-008-0890-8. Epub 2008 Dec 13. Cancer Chemother Pharmacol. 2009. PMID: 19082825 Free PMC article. Clinical Trial.
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. LoConte NK, et al. Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17. Invest New Drugs. 2015. PMID: 25318436 Free PMC article. Clinical Trial.
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ. Becher OJ, et al. Among authors: kolesar jm. Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26409. Epub 2016 Dec 30. Pediatr Blood Cancer. 2017. PMID: 28035748 Clinical Trial.
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Xu Y, Kolesar JM, Schaaf LJ, Drengler R, Duan W, Otterson G, Shapiro C, Kuhn J, Villalona-Calero MA. Xu Y, et al. Among authors: kolesar jm. Cancer Chemother Pharmacol. 2009 May;63(6):1073-82. doi: 10.1007/s00280-008-0826-3. Epub 2008 Sep 16. Cancer Chemother Pharmacol. 2009. PMID: 18795290 Free PMC article. Clinical Trial.
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. Mulkerin D, et al. Invest New Drugs. 2009 Oct;27(5):461-8. doi: 10.1007/s10637-008-9210-8. Epub 2009 Jan 8. Invest New Drugs. 2009. PMID: 19129971 Free PMC article. Clinical Trial.
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza-Delgado I, Schiller JH. Traynor AM, et al. Among authors: kolesar jm. J Thorac Oncol. 2009 Apr;4(4):522-6. doi: 10.1097/jto.0b013e3181952478. J Thorac Oncol. 2009. PMID: 19347984 Free PMC article. Clinical Trial.
212 results